Showing 2861-2870 of 5771 results for "".
- Luxa Biotechnology Presents Data from First-in-Human Retinal Pigment Epithelium Cell Therapy for Dry AMDhttps://modernod.com/news/luxa-biotechnology-presents-data-from-first-in-human-retinal-pigment-epithelium-cell-therapy-for-dry-amd/2482693/Luxa Biotechnology announced clinical data from its phase 1/2a clinical trial evaluating RPESC-RPE-4W, a proprietary retinal pigment epithelium (RPE) cell therapy for patients with dry age-related macular degeneration (AMD). The data were presented at the 77th Annual Wills Eye Conference in Phila
- Lumata Health Secures $23 Million Series B Fundinghttps://modernod.com/news/lumata-health-secures-23-million-series-b-funding/2482691/Lumata Health announced that it has raised $23 million in Series B funding, bringing its total raised since inception to $36 million. Lumata said the investment will enable the company to meet growing demand and further enhance the data-driven technology powering its patient adherence s
- FDA Approves Neurotech's Encelto as First and Only FDA-Approved Treatment for MacTelhttps://modernod.com/news/fda-approves-neurotechs-encelto-as-first-and-only-fda-approved-treatment-for-mactel/2482690/Neurotech Pharmaceuticals announced that the FDA has approved Encelto (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision
- Optos Unveils MonacoPro Ultra-Widefield and OCT Retinal Imaging Technologyhttps://modernod.com/news/optos-unveils-monacopro-ultra-widefield-and-oct-retinal-imaging-technology/2482688/Optos announced the launch of MonacoPro, the next generation ultra-widefield (UWF) SLO and spectral domain retinal imaging solution. Building on the legacy of Monaco, Optos said MonacoPro introduces features designed to elevate diagnostic precision and streamline workflow for eye care profes
- Haag-Streit Launches METIS 900 Ophthalmic Surgical Microscopehttps://modernod.com/news/haag-streit-launches-metis-900-new-ophthalmic-surgical-microscope/2482687/Haag-Streit announced the launch of the METIS 900 ophthalmic microscope system. According to Haag-Streit, the METIS 900 was designed to maximize clarity and precision of visualization during surgeries, as well as the surgeon’s comfort. Programmable hand and/or foot switches
- Adverum Initiates ARTEMIS Phase 3 Study to Evaluate Ixo-vec for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-initiates-artemis-phase-3-study-to-evaluate-ixo-vec-for-wet-amd/2482686/Adverum Biotechnologies announced the initiation of ARTEMIS phase 3 study to evaluate Ixo-vec gene therapy (ixoberogene soroparvovec) as a one-time intravitreal (IVT) injection for neovascular (wet) age-related macular degeneration (AMD). Wet AMD is a leading cause of blindness in the e
- Opthea Publishes Phase 2b Trial Data for Wet AMDhttps://modernod.com/news/opthea-publishes-promising-phase-2b-trial-data-for-wet-amd/2482685/Opthea announced new data from the phase 2b clinical trial using sozinibercept to treat wet age-related macular degeneration (AMD). The results were published in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. Opthea’s complete phase 3 wet AMD
- Altris AI Launches Advanced Optic Disc Analysis for Glaucomahttps://modernod.com/news/altris-ai-launches-advanced-optic-disc-analysis-for-glaucoma-complementing-gcc-asymmetry-analysis/2482683/Altris AI, a provider of AI OCT scan analysis for the detection of a range of retina pathologies and biomarkers, announced the launch of an advanced glaucoma 'Optic Disc Analysis' module. To address need to improve timely and accurate gl
- Formycon Receives Approval in the UK for Eylea Biosimilarhttps://modernod.com/news/formycon-receives-approval-in-the-uk-for-eylea-biosimilar/2482680/Formycon and its licensing partner Klinge Biopharma jointly announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved FYB203 (aflibercept), a biosimilar to Eylea (Regeneron), under the brand name Ahzantine. The approval covers the treatment
- Opus Genetics Doses First Pediatric Patient in Phase 1/2 Trial for OPGx-LCA5 Gene Therapyhttps://modernod.com/news/opus-genetics-doses-first-pediatric-patient-in-phase-12-trial-for-opgx-lca5-gene-therapy/2482675/Opus Genetics announced the first pediatric patient has been dosed in its ongoing phase 1/2 clinical trial evaluating OPGx-LCA5, its investigational gene therapy for Leber congenital amaurosis (LCA). Initial data from the pediatric cohort is expected to be shared by Q3